Sun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts cite Leqselvi launch costs, weak Taro performance, and high R&D spend as margin drags, even as domestic and specialty segments continue to drive overall growth.